Global Cell Therapy Raw Materials Market Revenue Grows at a CAGR of 18.18%

Introduction

Straits Research released its highly anticipated report, “Global Cell Therapy Raw Materials Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 5.34 billion in 2025 and is anticipated to grow to USD 23.96 billion by 2034, growing at a CAGR of 18.18% from 2026-2034.

Market Dynamics

Growth in the cell therapy raw materials market is driven by the rising shift toward customized formulations tailored to the distinct metabolic and functional requirements of T cells, stem cells, and engineered cell lines, which encourages closer collaboration between suppliers and therapy developers. However, market expansion faces restraint from the limited availability of large-batch GMP inputs required for high-volume allogeneic programs, as production capacity constraints and long qualification cycles slow procurement for commercial-scale operations. An opportunity emerges from the expansion of cryo-qualified supply chains that support long-distance distribution of temperature-sensitive media components, supplements, and reagents, enabling broader global access to standardized raw materials across clinical and commercial manufacturing hubs.

Key Highlights

• Product: By Product, the Cell Culture Supplements segment dominated the market with a revenue share of 27.78%.
• End Use: By End Use, the Biopharmaceutical & Pharmaceutical Companies segment dominated the market with a revenue share of 55.64%.
• Regional Insights: North America held a dominant share of the global market, accounting for 90.35%.

Competitive Players

1. Thermo Fisher Scientific
2. Merck KGaA
3. Sartorius AG
4. STEMCELL Technologies
5. Lonza
6. Miltenyi Biotec
7. Bio-Techne
8. BD
9. GE HealthCare
10. Corning Incorporated
11. Sartorius CellGenix GmbH
12. Charles River Laboratories
13. ACROBiosystems
14. Actylis
15. RoosterBio, Inc.
16. PromoCell
17. Repligen Corporation
18. Eppendorf SE
19. PBS Biotech, Inc.
20. Others

Recent Developments

December 2024: BioCentriq signed a long-term lease for a new manufacturing facility in Princeton, NJ, which served as its headquarters. The USD 12 million investment enhanced its capabilities in cell therapy development and production.

Segmentation

1. By Product (2026-2034)
   1. Media
   2. Sera
   3. Cell Culture Supplements
   4. Antibodies
   5. Reagents & Buffers
   6. Others
2. End Use (2026-2034)
   1. Biopharmaceutical & Pharmaceutical Companies
   2. CROs & CMOs
   3. Others